AR036832A1 - Compuestos derivados de himbacina, agonistas receptores de trombina, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de medicamentos - Google Patents
Compuestos derivados de himbacina, agonistas receptores de trombina, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de medicamentosInfo
- Publication number
- AR036832A1 AR036832A1 ARP020103876A ARP020103876A AR036832A1 AR 036832 A1 AR036832 A1 AR 036832A1 AR P020103876 A ARP020103876 A AR P020103876A AR P020103876 A ARP020103876 A AR P020103876A AR 036832 A1 AR036832 A1 AR 036832A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- aryl
- independently selected
- cycloalkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- FMPNFDSPHNUFOS-HQEQRHKESA-N Himbacine Natural products C(/[C@@H]1[C@H]2CCCC[C@@H]2C[C@@H]2C(=O)O[C@H]([C@H]12)C)=C\[C@@H]1CCC[C@H](C)N1C FMPNFDSPHNUFOS-HQEQRHKESA-N 0.000 title 1
- FMPNFDSPHNUFOS-UHFFFAOYSA-N N-Methyl-himandravin Natural products C12C(C)OC(=O)C2CC2CCCCC2C1C=CC1CCCC(C)N1C FMPNFDSPHNUFOS-UHFFFAOYSA-N 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- FMPNFDSPHNUFOS-LPJDIUFZSA-N himbacine Chemical compound C(/[C@@H]1[C@H]2CCCC[C@@H]2C[C@@H]2C(=O)O[C@H]([C@H]12)C)=C\[C@H]1CCC[C@H](C)N1C FMPNFDSPHNUFOS-LPJDIUFZSA-N 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 31
- 125000000217 alkyl group Chemical group 0.000 abstract 11
- 125000003118 aryl group Chemical group 0.000 abstract 11
- 229910052739 hydrogen Inorganic materials 0.000 abstract 10
- 125000001424 substituent group Chemical group 0.000 abstract 9
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 8
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 8
- 125000001072 heteroaryl group Chemical group 0.000 abstract 7
- -1 hydroxy, amino Chemical group 0.000 abstract 7
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 150000002367 halogens Chemical class 0.000 abstract 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 5
- 229910006069 SO3H Inorganic materials 0.000 abstract 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 1
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 abstract 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000006793 arrhythmia Effects 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 125000005347 halocycloalkyl group Chemical group 0.000 abstract 1
- 201000010235 heart cancer Diseases 0.000 abstract 1
- 208000024348 heart neoplasm Diseases 0.000 abstract 1
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Un compuesto derivado de himbacina representado por la fórmula estructural (1) o una sal farmacéuticamente aceptable de los mismos, en la cual R representa 1 a 3 sustituyentes independientemente seleccionados del grupo que consiste en H, alquilo C1-6, halógeno, hidroxi, amino, alquilo C1-6-amino, dialquilamino C1-6, alcoxi C1-6, -COR16, -COOR17, -SOR16, -SO2R16, -SO2NR17R18, -NR17SO2R18, -NR16COR16a, -NR16COOR16a, -NR16CONR4R5, flúor-alquilo C1-6, diflúor-alquilo C1-6, triflúor-alquilo C1-6, cicloalquilo C3-6, arilo-alquilo C1-6, hidroxi-alquilo C1-6, amino-alquilo C1-6, arilo y tio-alquilo C1-6; R1 y R2 están independientemente seleccionados del grupo que consiste en H, alquilo C1-6, flúor-alquilo C1-6, diflúor -alquilo C1-6, triflúor-alquilo C1-6, cicloalquilo C3-6, alquenilo C2-6, aril-alquilo C1-6, hidroxi-alquilo C1-6, amino-alquilo C1-6, arilo y tio-alquilo C1-6; ó R1 y R2 conjuntamente forman un grupo =O; R3 es H, hidroxi, alcoxi C1-6, ariloxi, aril-alquiloxi C1-6, heteroariloxi, heteroaril-alquiloxi C1-6, cicloalquiloxi C3-6, -SOR16, -SO2R17, -SO2NR18R19, -SR18, -SO3H, -C(O)OR17, -C(O)NR18R19, -OC(O)R32, -OC(O)NR33R34, -(CR33R34)nOR32, -NR4R5, -NR33COOR32, -NR33COR32, -NR33S(O)2R32, -NR33CONR33R34, -NR33S(O)2NR33R34, -(CR33R34)Nnr4r5, -(cr33r34)nNR33COOR32, -(CR33R34)nNR33COR32, -(CR33R34)nNR33S(O)R32, -(CR33R34)nNR33CONR33R34,-(CR33R34)nNR33S(O)2NR33R34, alquilo C1-6, halógeno, cicloalquilo C3-6, alquenilo C2-6, -CN, arilo, heteroarilo, heterocicloalquilo, -P(O)(OR7)2 ó alquilo C1-6 sustituido con 1 a 3 sustituyentes independientemente seleccionados del grupo que consiste en halógeno, -OH, -NH2, arilo, -COOH, -SO3H, tio y alquiltio C1-6; n es 1, 2, 3, ó 4; n1 y n2 son independientemente 0-3, con la condición de que ambos no sean 0; Het es un grupo heteroaromático mono-, bi- ó tricíclico C5-14 que comprende C1-13 y 1 a 4 heteroátomos independientemente seleccionados del grupo que consiste en N, O y S, donde un nitrógeno del anillo puede formar un N-óxido o un grupo cuaternario con un grupo alquilo C1-4, donde Het está adherido a B mediante un miembro de anillo de átomo de carbono y donde el grupo Het está sustituido con 1 a 4 sustituyentes, W, está independientemente seleccionado del grupo que consiste en alquilo C1-6; -NR4R5, -NHCOR26, -NHSO2R16, R21-arilo, arilo donde los átomos de carbono adyacentes forman un anillo con un grupo metilendioxi; y R21-heteroarilo; R4 y R5 están independientemente seleccionados del grupo que consiste en H, alquilo C1-6, fenilo, bencilo, y cicloalquilo C3-6, ó R4 y R5 conjuntamente son -(CH2)3-,-(CH2)4-,-(CH2)5- ó (CH2)2NR7-(CH2)2- y forman un anillo con el nitrógeno al cual están adheridos; R7 es H ó alquilo C1-6; R8, R10 y R11 están independientemente seleccionados del grupo que consiste en R1 y -OR1; R9 es H, OH, -NR4R5, alcoxi C1-6, halógeno o halo-alquilo C1-6; B es -(CH2)n3- ó cis ó trans -(CH2)n4CR12 =CR12a(CH2)n5, donde n3 es 0-5, n4 y n5 son independientemente 0-2, y R12 y R12a están independientemente seleccionados del grupo que consiste en H, alquilo C1-6 y halógeno; R16 y R16a están independientemente seleccionados del grupo que consiste en alquilo C1-6, fenilo y bencilo; R17, R18 y R19 están independientemente seleccionados del grupo que consiste en H, alquilo C1-6, fenilo y bencilo; R21 representa de 1 a 3 sustituyentes independientemente seleccionados del grupo que consiste en H, -CF3, -OCF3, halógeno, -NO2, alquilo C1-6, alcoxi C1-6, -NH2, alquiloC1-6-amino, di-(alquilo C1-6)amino, amino-alquilo C1-6, alquilamino C1-6 alquilo C1-6, di-(alquilo C1-6)-amino-alquilo C1-6, hidroxi-alquilo C1-6, -COOR17, -COR17, -CONR24R25, -NHCOR16, -NHSO2R16, NHSO2CH2CF3, -SO2NR24R25, -NR29C(O)NR24R25, -SO2R30, -P(O)(OR29)2, arilo, arilo-alquilo C1-6, heteroarilo, heterocicloalquilo, y -CR29(=NOR28); R22 es -COR23, -S(O)R31, -S(O)2R31, -SO2NR24R25 ó -COOR27; R23 es halo-alquilo C1-6, alquenilo C2-6, halo-alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, cicloalquilo C3-7-alquilo C1-6, cicloalquilo C3-7 sustituido con 1 a 3 sustituyentes seleccionados del grupo que consiste en halo, alcoxi C1-3-alquilo C1-3, hidroxi y alcoxi C1-6, arilo, aril-alquilo C2-6, heteroarilo, heterocicloalquilo, alquilo C1-6 sustituido con 1-3 sustituyentes independientemente seleccionados de -COOH y SO3H; ó fórmula (2) donde R35 y R36 están independientemente seleccionados del grupo que consiste en H, alquilo, o alquilo C1-6 sustituido con R37, donde R37 está seleccionado del grupo que consiste en HO-, HS-, -CH2S-, -NH2, fenilo, p-hidroxifenilo e indolilo; R24 y R25 están independientemente seleccionados del grupo que consiste en H, alquilo C1-6, halo-alquilo C1-6, alquenilo C2-6, haloa-alquilo C2-6, alquinilo C2-6, arilo, aril-alquilo C1-6, cicloalquilo C3-7, halo-cicloalquilo C3-7, alcoxi C1-3-alquilo C1-3, hidroxi y alcoxi C1-6; R26 es cicloalquilo C3-7, arilo, aril-alquilo C1-6, heteroarilo, heteroaril-alquilo C1-6 ó alquilamino C1-6; R27 es alquilo C1-6, fenilo, bencilo, alcoxi C1-3-alquilo C1-3, cicloalquilo C3-7, carboxi-alquilo C1-6, sulfo-alquilo C1-6 ó alquilo C1-6 sustituido con NR18R19 y carboxi; R28 es H, alquilo C1-6, fenilo, bencilo ó alcoxi C1-3-alquilo C1-3; R29 y R30 están independientemente seleccionados del grupo que consiste en H, alquilo C1-6; R31 es alquilo C1-6, halo-alquilo C1-6, alquenilo C2-6, halo-alquilo C2-6, alquinilo C2-6, cicloalquilo C3-7, cicloalquilo C3-7 sustituido con 1 a 3 sustituyentes seleccionados del grupo que consiste en halo, alcoxi C1-3-alquilo C1-3, hidroxi y alcoxi C1-6; arilo, aril-alquilo C1-6, heteroarilo, heterocicloalquilo, alquilo C1-6 sustituido con 1 a 3 sustituyentes independientemente seleccionados de -COOH y SO3H; ó alcoxi C1-6; R32 es R35-alquilo C1-6, R35-cicloalquilo C3-7, R35-alquenilo C2-6, R35-alquinilo C2-6 ó R35-arilo, donde R35 representa uno o dos sustituyentes independientemente seleccionados del grupo que consiste en H, -COOH, -NH2, -SO3H, =O y =NOR28; y R33 y R34 están independientemente seleccionados del grupo que consiste en H, alquilo C1-6 y cicloalquilo C3-7, así como también composiciones farmacéuticas que los contienen y un método para tratar enfermedades asociadas con trombosis, arteriosclerosis, restenosis, hipertensión, angina pectoris, arritmia, insuficiencia cardíaca y cáncer mediante la administración de dichos compuestos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33035901P | 2001-10-18 | 2001-10-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR036832A1 true AR036832A1 (es) | 2004-10-06 |
Family
ID=23289411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020103876A AR036832A1 (es) | 2001-10-18 | 2002-10-16 | Compuestos derivados de himbacina, agonistas receptores de trombina, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de medicamentos |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US7037920B2 (es) |
| EP (1) | EP1436298B1 (es) |
| JP (2) | JP4307260B2 (es) |
| KR (1) | KR100960170B1 (es) |
| CN (1) | CN100369917C (es) |
| AR (1) | AR036832A1 (es) |
| AT (1) | ATE525378T1 (es) |
| AU (1) | AU2002335031C1 (es) |
| BR (1) | BR0213967A (es) |
| CA (1) | CA2463628A1 (es) |
| CO (1) | CO5570668A2 (es) |
| EC (1) | ECSP045064A (es) |
| HU (1) | HUP0500443A3 (es) |
| IL (1) | IL160918A0 (es) |
| MX (1) | MXPA04003610A (es) |
| MY (1) | MY139335A (es) |
| NO (1) | NO329349B1 (es) |
| NZ (1) | NZ531869A (es) |
| PE (1) | PE20030808A1 (es) |
| PL (1) | PL371948A1 (es) |
| RU (1) | RU2319704C9 (es) |
| WO (1) | WO2003033501A1 (es) |
| ZA (1) | ZA200402849B (es) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6346510B1 (en) | 1995-10-23 | 2002-02-12 | The Children's Medical Center Corporation | Therapeutic antiangiogenic endostatin compositions |
| US7488742B2 (en) * | 2000-06-15 | 2009-02-10 | Schering Corporation | Thrombin receptor antagonists |
| US7235567B2 (en) * | 2000-06-15 | 2007-06-26 | Schering Corporation | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist |
| PT1495018E (pt) | 2002-04-16 | 2008-02-19 | Schering Corp | Antagonistas tricíclicos de receptores de trombina |
| US20070243632A1 (en) * | 2003-07-08 | 2007-10-18 | Coller Barry S | Methods for measuring platelet reactivity of patients that have received drug eluting stents |
| EP1641492B1 (en) * | 2003-07-08 | 2011-12-14 | Accumetrics, Inc. | Controlled platelet activation to monitor therapy of adp antagonists |
| ES2311996T3 (es) * | 2004-05-28 | 2009-02-16 | Schering Corporation | Analogos retringidos de himbacina como antagonistas del receptor de trombina. |
| CA2576971A1 (en) * | 2004-08-20 | 2006-03-02 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
| JP2008515908A (ja) * | 2004-10-06 | 2008-05-15 | ユニバーシティー オブ ロチェスター | 組織因子経路を阻害する薬剤を使用する、肺高血圧症の治療 |
| RU2408594C2 (ru) * | 2004-10-08 | 2011-01-10 | Шеринг Корпорейшн | Антагонисты рецептора тромбина |
| ATE458726T1 (de) * | 2005-01-14 | 2010-03-15 | Schering Corp | Exo- und diastereoselektive synthese von himbacin-analoga |
| ATE500249T1 (de) * | 2005-01-14 | 2011-03-15 | Schering Corp | Synthese von himbacinanaloga |
| MX2007008622A (es) * | 2005-01-14 | 2007-09-11 | Schering Corp | Una sintesis exo-selectiva de analogos de himbacina. |
| MX2007012091A (es) * | 2005-03-31 | 2007-11-20 | Schering Corp | Antagonistas espirociclicos de los receptores de trombina. |
| US7595169B2 (en) * | 2005-04-27 | 2009-09-29 | Accumetrics, Inc. | Method for determining percent platelet aggregation |
| WO2007075808A2 (en) * | 2005-12-20 | 2007-07-05 | Schering Corporation | Methods for preventing and/or treating a cell proliferative disorder |
| EP1966203B1 (en) * | 2005-12-22 | 2013-11-13 | Merck Sharp & Dohme Corp. | Oxazoloisoquinoline derivatives as thrombin receptor antagonists |
| JP2009521472A (ja) * | 2005-12-22 | 2009-06-04 | シェーリング コーポレイション | 心肺手術の合併症の予防としてのトロンビンレセプターアンタゴニスト |
| JP2009534308A (ja) * | 2006-03-29 | 2009-09-24 | シェーリング コーポレイション | トロンビン受容体アンタゴニストとして有用なトロンビン受容体アンタゴニスト |
| KR20080110880A (ko) * | 2006-04-13 | 2008-12-19 | 쉐링 코포레이션 | 융합된 환 트롬빈 수용체 길항제 |
| AU2007269830A1 (en) | 2006-06-29 | 2008-01-10 | Schering Corporation | Substituted bicyclic and tricyclic thrombin receptor antagonists |
| AR061727A1 (es) * | 2006-06-30 | 2008-09-17 | Schering Corp | Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato |
| TWI367112B (en) | 2006-06-30 | 2012-07-01 | Schering Corp | Immediate-release tablet formulations of a thrombin receptor antagonist |
| TWI343262B (en) * | 2006-09-26 | 2011-06-11 | Schering Corp | Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist |
| CN101541782A (zh) * | 2006-10-04 | 2009-09-23 | 先灵公司 | 作为凝血酶受体拮抗剂的二环和三环衍生物 |
| JP2010505836A (ja) * | 2006-10-04 | 2010-02-25 | シェーリング コーポレイション | ヒンバシンの修飾された三環単位に基づいたトロンビン受容体アンタゴニスト |
| MX2009006873A (es) * | 2006-12-22 | 2009-07-03 | Schering Corp | Promotores de desintegracion en formulaciones de granulacion humeda de dosis solida. |
| EP2134344A1 (en) * | 2007-03-23 | 2009-12-23 | Schering Corporation | Reduction of adverse events.after percutaneous intervention by use of a thrombin receptor antagonist |
| EP2153235B1 (en) * | 2007-05-03 | 2012-05-16 | Accumetrics, Inc. | Methods of measuring inhibition of platelet aggregation by thrombin receptor antagonists |
| CA2713550C (en) | 2008-02-05 | 2016-06-14 | Sanofi-Aventis | Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments |
| EP2300435A2 (en) | 2008-05-19 | 2011-03-30 | Schering Corporation | Heterocyclic compounds as factor ixa inhibitors |
| DK2438060T3 (da) | 2009-06-04 | 2014-01-13 | Merck Sharp & Dohme | Aktiv metabolit af en trombin-receptor-antagonist |
| CA2764172A1 (en) | 2009-06-08 | 2010-12-16 | Schering Corporation | A thrombin receptor antagonist and clopidogrel fixed dose tablet |
| WO2011017296A1 (en) | 2009-08-04 | 2011-02-10 | Schering Corporation | 4, 5, 6-trisubstituted pyrimidine derivatives as factor ixa inhibitors |
| WO2013134012A1 (en) | 2012-03-06 | 2013-09-12 | Merck Sharp & Dohme Corp. | Preparation and use of bicyclic himbacine derivatives as par-receptor antagonists |
| EP3035930A4 (en) | 2013-08-22 | 2017-03-08 | Merck Sharp & Dohme Corp. | 7a-heterocycle substituted- 6, 6-difluoro bicyclic himbacine derivatives |
| EP3035928B1 (en) | 2013-08-22 | 2023-10-18 | Merck Sharp & Dohme LLC | 3'-pyridyl substituted- 6,6-difluoro bicyclic himbacine derivatives |
| EP3035929B1 (en) | 2013-08-22 | 2024-07-03 | Merck Sharp & Dohme LLC | 7a-amide substituted-6,6-difluoro bicyclic himbacine derivatives |
| US9969724B2 (en) | 2014-04-16 | 2018-05-15 | Merck Sharp & Dohme Corp. | Factor IXa inhibitors |
| CN104610330A (zh) * | 2015-02-25 | 2015-05-13 | 成都安斯利生物医药有限公司 | 一种制备(e)-3-丙烯酸乙酯频呐硼酸酯的方法 |
| CN116133660B (zh) | 2020-07-22 | 2025-05-02 | 詹森药业有限公司 | 可用作因子XIa抑制剂的化合物 |
| US11919881B2 (en) | 2021-03-18 | 2024-03-05 | Janssen Pharmaceutica Nv | Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors |
| US11845748B2 (en) | 2021-03-18 | 2023-12-19 | Janssen Pharmaceutica Nv | Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors |
| US11814364B2 (en) | 2021-03-18 | 2023-11-14 | Janssen Pharmaceutica Nv | Pyridine N-oxide derivatives useful as factor XIa inhibitors |
| US11897880B2 (en) | 2021-04-30 | 2024-02-13 | Janssen Pharmaceutica Nv | 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors |
| US12286429B2 (en) | 2021-07-22 | 2025-04-29 | Janssen Pharmaceutica Nv | 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide derivatives useful as a factor XIa inhibitors |
| US11958856B2 (en) | 2021-07-22 | 2024-04-16 | Janssen Pharmaceutica Nv | Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5716952A (en) * | 1992-03-18 | 1998-02-10 | Allergan | Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists |
| IL106197A (en) | 1992-07-30 | 1999-11-30 | Cor Therapeutics Inc | Agagonists for the rhombin receptors and pharmaceutical preparations containing them |
| JP2000229961A (ja) * | 1998-12-11 | 2000-08-22 | Sagami Chem Res Center | ヒドロナフト［２，３−ｃ］フラン誘導体およびその製造方法 |
| US6063847A (en) * | 1997-11-25 | 2000-05-16 | Schering Corporation | Thrombin receptor antagonists |
| WO1999026943A1 (en) * | 1997-11-25 | 1999-06-03 | Schering Corporation | Thrombin receptor antagonists |
| DE19801636A1 (de) * | 1998-01-17 | 1999-07-22 | Bayer Ag | Substituierte bicyclische Lactone |
| MXPA02012447A (es) | 2000-06-15 | 2003-04-25 | Schering Corp | Antagonistas receptores de trombina. |
-
2002
- 2002-10-16 AR ARP020103876A patent/AR036832A1/es unknown
- 2002-10-16 CA CA002463628A patent/CA2463628A1/en not_active Abandoned
- 2002-10-16 AU AU2002335031A patent/AU2002335031C1/en not_active Ceased
- 2002-10-16 EP EP02801732A patent/EP1436298B1/en not_active Expired - Lifetime
- 2002-10-16 IL IL16091802A patent/IL160918A0/xx not_active IP Right Cessation
- 2002-10-16 RU RU2004115114/04A patent/RU2319704C9/ru not_active IP Right Cessation
- 2002-10-16 MX MXPA04003610A patent/MXPA04003610A/es active IP Right Grant
- 2002-10-16 MY MYPI20023859A patent/MY139335A/en unknown
- 2002-10-16 AT AT02801732T patent/ATE525378T1/de not_active IP Right Cessation
- 2002-10-16 BR BR0213967-7A patent/BR0213967A/pt not_active IP Right Cessation
- 2002-10-16 JP JP2003536240A patent/JP4307260B2/ja not_active Expired - Fee Related
- 2002-10-16 NZ NZ531869A patent/NZ531869A/en not_active IP Right Cessation
- 2002-10-16 WO PCT/US2002/032936 patent/WO2003033501A1/en not_active Ceased
- 2002-10-16 PE PE2002001022A patent/PE20030808A1/es not_active Application Discontinuation
- 2002-10-16 HU HU0500443A patent/HUP0500443A3/hu unknown
- 2002-10-16 PL PL02371948A patent/PL371948A1/xx not_active Application Discontinuation
- 2002-10-16 CN CNB028206665A patent/CN100369917C/zh not_active Expired - Fee Related
- 2002-10-16 US US10/271,715 patent/US7037920B2/en not_active Expired - Fee Related
- 2002-10-16 KR KR1020047005435A patent/KR100960170B1/ko not_active Expired - Fee Related
-
2004
- 2004-04-15 EC EC2004005064A patent/ECSP045064A/es unknown
- 2004-04-15 ZA ZA200402849A patent/ZA200402849B/xx unknown
- 2004-04-16 CO CO04034781A patent/CO5570668A2/es not_active Application Discontinuation
- 2004-05-14 NO NO20042021A patent/NO329349B1/no not_active IP Right Cessation
-
2005
- 2005-12-19 US US11/311,083 patent/US20060106050A1/en not_active Abandoned
-
2008
- 2008-09-17 JP JP2008238716A patent/JP2009029820A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR036832A1 (es) | Compuestos derivados de himbacina, agonistas receptores de trombina, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de medicamentos | |
| ES2525763T3 (es) | Derivados del ácido fenilalcanoico sustituido y sus usos para el tratamiento de enfermedades respiratorias | |
| PE20230249A1 (es) | Compuestos de heteroarilo biciclicos y usos de estos | |
| AR039570A1 (es) | Antagonistas de los receptores de trombina | |
| AR044401A1 (es) | Compuestos derivados de quinoleina, procedimientos para su preparacion, composiciones farmaceuticas que los contienen y su empleo en la fabricacion de medicamentos. | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| AR054397A1 (es) | Derivados de 2-carbamida-4-feniltiazol, su preparacion, composicion farmaceutica que los contiene y compuesto intermediario | |
| PE20050274A1 (es) | Inhibidores del factor inhibidor de la migracion de los macrofagos y metodos para su identificacion | |
| AR053092A1 (es) | Compuestos derivados de acido fenoxiacetico y compuestos intermediarios de sintesis | |
| AR054809A1 (es) | Compuestos de amino -5-heteroarilo (5 miembros) imidazolona y su uso para la modulacion de la b- secretasa | |
| AR058287A1 (es) | Derivados de isoquinolina y composicion farmaceutica | |
| AR061651A1 (es) | Analogos de piridina ii | |
| CY1112703T1 (el) | Υποκατεστημενες πιπεριδινο-διϋδρο-θειενο-πυριμιδινες | |
| AR038419A1 (es) | Derivados de piridina y quinolina | |
| PE20091376A1 (es) | Derivados de fenilamino como moduladores de beta-amiloide | |
| AR074817A1 (es) | Dihidropiridona-amidas como moduladores de p2x7 | |
| NO20065184L (no) | 1-amino-ftalazinderivater, deres fremstilling og terapeutiske anvendelse derav | |
| EA200701991A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ИМИДАЗО [1,5-a]ПИРИДИНОВ, СПОСОБ ИХ ПОЛУЧЕНИЯ И СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ | |
| AR053566A1 (es) | Compuestos espiriciclicos antagonistas de los receptores de trombina | |
| AR044511A1 (es) | Procedimiento para resolver triazinas utilizadas en el tratamiento de sindrome de resistencia a la insulina | |
| AR061835A1 (es) | Derivados tetraciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| BR0315800A (pt) | Derivados de imidazopiridina, seu processo de preparação e as composições farmacêuticas que os contêm | |
| AR051334A1 (es) | Derivados de 2- amido-4-feniltiazol | |
| AR071587A1 (es) | Compuestos heterociclicos como inhibidores de mek | |
| PE20251600A1 (es) | Compuestos que contienen heteroatomos y usos de estos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |